Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

761.50 -28.30 (-3.58%)
Official Closing Price Updated: 7:00 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together'
Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation. 
Via Stocktwits
Topics ETFs Economy Government
Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season
These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025 
Via MarketBeat
Topics Economy World Trade
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon." 
Via Investor's Business Daily
Topics ETFs Economy Government
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes. 
Via Benzinga
WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation
WeightWatchers completes reorganization, adds new leadership and unveils a women's health initiative targeting menopause care. 
Via Benzinga
LVM Capital Management Loads Up on NOC, Buys 6,237 Shares in Q2 2025
LVM Capital Management bought a $3.16 million stake in Northrop Grumman last quarter. 
Via The Motley Fool
Topics Regulatory Compliance
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
Via The Motley Fool
Topics Regulatory Compliance
2 S&P 500 Dividend Stocks That Could Climb 17% or More, According to Wall Street
Via The Motley Fool
Topics Stocks
3 Underrated Dividend Growth Stocks to Buy and Hold for Years
Via The Motley Fool
Topics World Trade
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock. 
Via Benzinga
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns. 
Via Benzinga
Michael McTague: The pharmaceutical giants leading the market-cap parade in 2025
Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market capitalization has risen farthest? Whose 
Via Equities.com
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert
Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access. 
Via Benzinga
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Via The Motley Fool
Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...'
Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery. 
Via Benzinga
Topics Artificial Intelligence
2 Stocks to Buy on the Dip and Hold for 10 Years
Via The Motley Fool
2 Dividend Growth Stocks to Buy and Hold Forever
Via The Motley Fool
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies . 
Via Benzinga
Topics Government
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Via The Motley Fool
Topics Artificial Intelligence
The 9 Best Stocks to Buy Now in July (2025)
Via The Motley Fool
Topics Artificial Intelligence
1 Unstoppable Vanguard Growth ETF to Buy With $400 in July
Via The Motley Fool
Topics Artificial Intelligence ETFs
2 Cash-Producing Stocks Worth Investigating and 1 to Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Can Buying the Vanguard S&P 500 ETF Make You a Millionaire?
Via The Motley Fool
Topics ETFs Economy Stocks
2 Growth Stocks to Buy Hand Over Fist in July
These companies are poised to produce fireworks for your portfolio over the coming years. 
Via The Motley Fool
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
Via The Motley Fool
The health-care stocks to watch as treatment innovations shake up patient care
Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of health-care companies to 
Via Equities.com
Topics Economy
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.